Deutsche Bank cut shares of Hologic (NASDAQ:HOLX) from a buy rating to a hold rating in a research report released on Friday, January 19th, MarketBeat reports. They currently have $49.00 price objective on the medical equipment provider’s stock.
HOLX has been the subject of a number of other research reports. BidaskClub lowered Hologic from a hold rating to a sell rating in a research note on Saturday, January 13th. Evercore ISI initiated coverage on Hologic in a research note on Wednesday, January 3rd. They issued an outperform rating and a $50.00 price target for the company. Cowen raised Hologic from a market perform rating to an outperform rating and set a $51.00 price target for the company in a research note on Monday, December 11th. Piper Jaffray Companies reiterated a buy rating and issued a $48.00 price objective on shares of Hologic in a report on Thursday, November 9th. Finally, Zacks Investment Research upgraded Hologic from a sell rating to a hold rating in a report on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $48.00.
Shares of Hologic (NASDAQ HOLX) traded up $0.23 on Friday, hitting $38.03. The stock had a trading volume of 3,320,000 shares, compared to its average volume of 3,000,000. Hologic has a 12-month low of $35.33 and a 12-month high of $46.80. The company has a market capitalization of $10,520.00, a PE ratio of 14.52, a PEG ratio of 1.72 and a beta of 0.77. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25.
Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.05. The business had revenue of $791.10 million during the quarter, compared to analyst estimates of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. Hologic’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.52 earnings per share. equities analysts expect that Hologic will post 2.25 earnings per share for the current year.
In other news, Director Namal Nawana bought 6,600 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were acquired at an average cost of $37.88 per share, with a total value of $250,008.00. Following the completion of the transaction, the director now owns 6,954 shares of the company’s stock, valued at approximately $263,417.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. Company insiders own 0.88% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Cornerstone Capital Management Holdings LLC. lifted its position in shares of Hologic by 8.7% during the 4th quarter. Cornerstone Capital Management Holdings LLC. now owns 51,831 shares of the medical equipment provider’s stock valued at $2,214,000 after buying an additional 4,167 shares in the last quarter. OLD Mission Capital LLC purchased a new position in shares of Hologic during the 4th quarter valued at about $387,000. Tyers Asset Management LLC lifted its position in shares of Hologic by 9.2% during the 4th quarter. Tyers Asset Management LLC now owns 15,568 shares of the medical equipment provider’s stock valued at $666,000 after buying an additional 1,316 shares in the last quarter. Paloma Partners Management Co lifted its position in shares of Hologic by 174.0% during the 4th quarter. Paloma Partners Management Co now owns 33,846 shares of the medical equipment provider’s stock valued at $1,447,000 after buying an additional 21,494 shares in the last quarter. Finally, Raymond James & Associates lifted its position in shares of Hologic by 19.4% during the 4th quarter. Raymond James & Associates now owns 74,354 shares of the medical equipment provider’s stock valued at $3,179,000 after buying an additional 12,068 shares in the last quarter. 93.84% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Hologic (NASDAQ:HOLX) Downgraded to Hold at Deutsche Bank” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/14/hologic-holx-downgraded-by-deutsche-bank-to-hold.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.